HOME CANCER GLOSSARY  CANCER PHOTOS  NEW CANCER BOOKS  LINKING  ADVERTISE

   
 

Free Financial Help for Cancer Patients
Gov't regulated program

Breast Cancer "Switch" Found

Cancer Pictures

Best Natl Cancer Ctrs

Cancer Centers
by State


Cancer Societies

Newest Treatments
by cancer type

MyCancerNews.com

Cancer Newsletters

Medical Journals

Cancer Calculator

Nat'l Cancer Inst.

MedLine Cancer

Chemotherapy

Other helpful links

Additional Help
for Cancer Patients

More Cancer Photos

Women's Health

More Than Mammograms: MRI for High-Risk Women


Medically Reviewed On: October 05, 2004

Physicians and women have long awaited a better early detection tool for breast cancer than mammograms. And a recent study suggests that a new option, magnetic resonance imaging (MRI), can be added to the screening arsenal, though it's only recommended to women at high genetic risk for breast cancer.

Breast cancer screening is a top concern for women who have an inherited abnormality in one of two genes, known as the BRCA1 and BRCA2 genes. Yet few studies have examined what screening approach is best for these high-risk women. BRCA1 and BRCA2 mutation carriers are identified though blood tests that are given to certain women with a strong family history of breast cancer. Women of Ashkenazi Jewish descent are at particular risk: The mutations occur in about 2.5 percent of these women, compared to 1 percent of the general population.

A study published in the September 15th issue of the Journal of the American Medical Association looked at the usefulness of MRI, mammograms, ultrasound and clinical breast exams, which are breast exams performed by a healthcare professional, in screening healthy women with the BRCA1 and BRCA2 gene mutations for breast cancer. The researchers found that MRI, in which magnets and radiowaves create an image of a body part, was a helpful addition to the surveillance programs for these women.

Other risk factors for breast cancer include age, family history, use of hormone replacement therapy, radiation exposure, early onset of the menstrual period and late menopause. However, the JAMA study only examined women with one of the BRCA mutations. Breast cancers related to BRCA1 or 2 mutations make up about 5 percent of all breast cancers.

Below, study author Sandra Messner, MD, the medical coordinator of clinical breast services in preventive oncology at the Toronto Sunnybrook Regional Cancer Center, discusses the best screening options for these high-risk women to help make sure any breast cancer they develop is detected as early as possible.

What are the BRCA mutations?
There are two large genes that have been identified in all women called BRCA1 and BRCA2. They function, we think, as tumor-suppressor genes, so they keep cancers from developing. If they are abnormal or what we call mutated, then your risk of cancer is increased, and the risk of breast cancer and ovarian cancer particularly is affected. If a woman carries an abnormality in one of those two genes, she is thought to have up to an 85 percent lifetime risk of breast cancer. The average woman's lifetime risk of developing breast cancer is about 11 percent. The mutations also increase the risk of ovarian cancer, more so with BRCA1 than with BRCA2. The BRCA2 mutations may also increase risk of other cancers, such as melanoma and pancreatic cancer.

Page 1 of 3 Next Page >>

 

Alternative Therapies

Melanoma Skin Cancer

Complementary and Alternative Cancer
Care Guidelines

Cancer Treatment Research Library

Dangerous Doctors
...is yours safe?

Cancer Archives

 

 

MEMBERSHIPS:     

About us
Privacy policy
Conditions of use

 


Nat'l Cervical
Cancer Coalition

logo nbtf
National Brain
Tumor
Foundation


Nat'l Ovarian
Cancer Coalition


Breast Cancer
Research

MCN
My
Cancer News

 

Special
Thanks
 TECH SUPPORT

Codebrain
Codebelly


NOTICE:  No information on this CANCER research site is provided, intended or implied to substitute for trained, professional medical advice, CANCER diagnosis or CANCER treatmentAs a condition of use of this cancer website, all visitors agree to seek trained medical advice before using any cancer treatment or cancer information found on this website and agree discuss these with their physicians prior to use and to hold RobertsReview and all entities affiliated with, contributing to, and/or operating this cancer research website harmless in regard to all information provided herein and/or from any decisions that may flow from use of this information.  RobertsReview in no way recommends, endorses or verifies the accuracy or claims of any of the cancer information provided herein by "third parties" regardless of their affiliation.

©1997-2006 RobertsReview, Wickford, RI USA. No information contained on this website may be reproduced in any form in any media.  Single copies may be reprinted for non-commercial use.